TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3925630
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of vinblastine, thiotepa, and 5-fluorouracil once a week
Study: 3925630
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of vinblastine on days 1 and 2, thiotepa on day 3, and 5-fluorouracil on day 5, weekly
Study: 23844826
Drug: Protective creams
Normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective creams (PCs) applied at a low dose (2 mg/cm²)
Study: 23844826
Drug: Protective creams
Normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective creams (PCs) applied at a high dose (20 mg/cm²)
Study: 18047870
Drug: Social communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social communication skills training (12 weekly group sessions, 1.5 hours each)
Study: 12177793
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(‐1) x wk(‐1)
Study: 12177793
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa at an initial dose of 150 U x kg(‐1) three times weekly
Study: 12177793
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa at an initial dose of 40,000 U x wk(‐1)
Study: 10023731
Drug: Navy's usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navy's usual treatment (exercise alone)
Study: 7589031
Drug: Zileuton 200
Normalized name: zileuton 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 200 mg
Study: 7589031
Drug: Zileuton 400
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton 400 mg
Study: 29738286
Drug: Self-limiting excavation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-limiting excavation protocol using chemomechanical Carisolv gel/operating microscope
Study: 25117817
Drug: Concurrent trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent trastuzumab (Arm C)
Study: 25117817
Drug: Sequential trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential trastuzumab after chemotherapy (Arm B)
Study: 9708936
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Arm A)
Study: 22300946
Drug: HIV treatment-naive
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV treatment-naive patients
Study: 22300946
Drug: Overall gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall gene expression across all treatment groups
Study: 16142594
Drug: Fluvastatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin, 80 mg, p.o.
Study: 23549582
Drug: V710 vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: V710 vaccine, 60 μg (n = 4015)
Study: 19494217
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg subcutaneously every 8 weeks
Study: 15121733
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 5000 U/day plus low-dose aspirin
Study: 15121733
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment intervention)
Study: 30197142
Drug: Inoculation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculation with 5 mL + 120 mL of sterile PBS (control; n = 12)
Study: 12358250
Drug: Bran (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bran (15 g b.i.d.)
Study: 30680828
Drug: Bimonthly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimonthly administration of Cetuximab at 500 mg/m2
Study: 30680828
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of Cetuximab at 250 mg/m2
Study: 27645341
Drug: Daclizumab 150mg
Normalized name: DACLIZUMAB 150MG/ML SYR
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab 150mg or 300mg monthly
Study: 17538805
Drug: 3% terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% terbinafine emulsion gel
Study: 17538805
Drug: 1% terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% terbinafine emulsion gel
Study: 9891541
Drug: Induction platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction platinum based chemotherapy
Study: 4827463
Drug: Diazepam (Valium),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (Valium), 20 mg daily for at least 5 consecutive days
Study: 27543211
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (TCS) alone
Study: 27543211
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (TCS) + dilute bleach bath
Study: 15068851
Drug: Long-term HAART
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term HAART treatment
Study: 15068851
Drug: Single structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single structured therapy interruption (STI)
Study: 11176590
Drug: Ofloxacin (Floxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (Floxin otic)
Study: 11176590
Drug: Oral amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin/clavulanate (Augmentin)
Study: 7916278
Drug: Inactivated MUKC
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated MUKC vaccine (3 doses)
Study: 16301238
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg ropivacaine (7.5 mg/mL) alone (control group)
Study: 16301238
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg ropivacaine combined with 75 mug clonidine (clonidine group)
Study: 31204605
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT; n= 21)
Study: 31932513
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.8 mg with enalapril 10 mg
Study: 29273594
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg alone
Study: 26550817
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of hyaluronic acid (HA) + oral viscosupplementation (IA)
Study: 26550817
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of hyaluronic acid (HA) only
Study: 10440419
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg
Study: 14738561
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) therapy
Study: 8432223
Drug: Acarbose 25
Normalized name: acarbose 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 25 mg powdered, 3 times a day with meals for 3 months
Study: 3829440
Drug: S-carboxymethylcysteine (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-carboxymethylcysteine (2.25 g per day for 7 days)
Study: 31791364
Drug: Exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise plus Nutrition (Combination)
Study: 31791364
Drug: Exercise, Nutrition,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise, Nutrition, and Combination groups
Study: 30320657
Drug: Lavender oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender oil inhalation (2 drops placed 15 to 20 cm away from the pillow, 30 minutes before bed for 1 week)
Study: 31567306
Drug: Lavender oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender oil inhalation
Study: 29325238
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication
Study: 17215186
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B12 supplementation (500 microg)
Study: 8317404
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac tromethamine (KT)
Study: 30033064
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (20 mg) and 2 injections of normal saline (group B)
Study: 30033064
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (20 mg) and 2 injections of low-dose (10 mg) dexamethasone (group C)
Study: 23228033
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with clinical‐radiological severity mismatch (NIHSS score ≥ 10 and infarct volume <20 cc)
Study: 23228033
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with NIHSS score ≥ 10 and infarct volume ≥ 20 cc
Study: 21942462
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI) users
Study: 21942462
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI) users (low adherence)
Study: 21942462
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI) users (medium adherence)
Study: 21942462
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI) users (high adherence)
Study: 30449719
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg every 3 weeks for 6 cycles followed by single-agent bevacizumab for 12 further cycles (total duration 12 months)
Study: 25164872
Drug: Exogenous surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous surfactant (200 mg/kg poractant alfa) via the Hobart method
Study: 18922386
Drug: Camu-camu juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camu-camu juice (70 ml daily for 7 days, 1050 mg of vitamin C)
Study: 9272342
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccines
Study: 10732318
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg
Study: 25858239
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment following intravenous tissue-type plasminogen activator
Study: 26012639
Drug: Intravenous tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue-type plasminogen activator alone
Study: 19590458
Drug: CEE/MPA (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Study: 15497663
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg tablets
Study: 15497663
Drug: Azithromycin 200
Normalized name: AZITHROMYCIN 200MG/5ML SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 200 mg/5 mL suspension
Study: 9331518
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg once daily for 10 days
Study: 9331518
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg once daily for 10 days + Selegiline 10 mg once daily for 4 days
Study: 2831262
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NS) 1% solution, 0.13 ml nasal spray, administered at least twice daily
Study: 10371003
Drug: Interocclusal appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interocclusal appliance therapy
Study: 8592096
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of epinephrine at 12.5, 25, and 50 ng/(kg x min) for 1 hour each
Study: 8470415
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution
Study: 10149510
Drug: Heparin-coated cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated cardiopulmonary bypass circuits
Study: 6362341
Drug: 50-150 mg
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-150 mg Slow Apresoline once daily
Study: 26831302
Drug: Liraglutide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.6 mg for 7 days, 1.2 mg for 7 days, and 1.8 mg for 3 days)
Study: 15808246
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection of 5 ml of a 50:50 mixture of 4% lidocaine and 0.75% bupivacaine
Study: 15808246
Drug: Sub-Tenon's capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon's capsule injection of 5 ml of a 50:50 mixture of 4% lidocaine and 0.75% bupivacaine
Study: 1313068
Drug: Dexamethasone 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.6 mg/kg intravenously as a loading dose followed by 0.2 mg/kg every 6 h for 5 days
Study: 18155988
Drug: Higher-energy-density entrée
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-energy-density entrée (2.0 kcal/g)
Study: 1364273
Drug: Oxatomide (Tinset)
Normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (Tinset) tablets
Study: 27075863
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg and 80 mg
Study: 17914201
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% cyclosporine drops
Study: 15384858
Drug: Urokinase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase therapy
Study: 2688602
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg
Study: 3555588
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg (C50)
Study: 3555588
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg (HCTZ 25)
Study: 3555588
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg and Hydrochlorothiazide 25 mg (C50/HCTZ 25)
Study: 31634877
Drug: Medication Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Therapy Management program (MTM)
Study: 19019476
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 microg twice-daily
Study: 17955656
Drug: Lianbai liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lianbai liquid (treatment group)
Study: 15763649
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) comprising vincristine, etoposide, carboplatin, and cyclophosphamide followed by craniospinal RT 35 Gy/21 fractions with a posterior fossa boost 20 Gy/12 fractions.
Study: 15763649
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) followed by craniospinal RT with a metastatic boost.
Study: 15763649
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) prior to RT.
Study: 12197849
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (81 mg daily for 7 days)
Study: 9860148
Drug: M2 (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2 (reference mefloquine tablet)
Study: 1263629
Drug: Nurse practitioner
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse practitioner with more frequent and longer patient visits, ordered more medications, less physician consultation.
Study: 21291323
Drug: 2.0 million
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 million international units of IL-2 subcutaneously daily during the final 2 weeks of treatment interruption and the first week of treatment reinitiation (Arm A)
Study: 17268388
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BT-A) injections (3 successive doses to the calf muscle bilaterally at intervals of 3 to 4 months)
Study: 30511430
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste with amoxicillin (TAPa)
Study: 30511430
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste with cefaclor (TAPc)
Study: 30511430
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste with doxycycline (TAPd)
Study: 30511430
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste with minocycline (TAPm)
Study: 26076302
Drug: Water spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water spray
Study: 16778714
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg after pretreatment with clarithromycin 800 mg/d
Study: 16778714
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg after pretreatment with fluvoxamine 50 mg/d
Study: 3379143
Drug: Haloperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5 mg intramuscularly or 1.0 mg orally)
Study: 26554316
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual in an open general psychiatric ward
Study: 22983284
Drug: Glycyrrhizin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (75 mg three times daily for 6 days)
Study: 19705923
Drug: meloxicam 30
Normalized name: meloxicam 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 30 mg with cholestyramine
Study: 8771595
Drug: loprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: loprazolam (1 mg)
Study: 1607582
Drug: Encainide, flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide, flecainide or moricizine (upwardly titrated doses)
Study: 21641362
Drug: Adiponectin greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adiponectin greater than the median (4,477 ng/mL)
Study: 9143000
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) 10 micrograms
Study: 9143000
Drug: Adrenocorticotropic hormone
Normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenocorticotropic hormone (ACTH) 1 microgram
Study: 18266664
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of antipsychotics
Study: 25416723
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg in 11/15 patients)
Study: 25416723
Drug: High-dose glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucocorticoids (n=11) or physiological replacement doses (n=4)
Study: 31485774
Drug: Concentrations of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrations of two terpenoid compounds (β‐caryophyllene, α‐humulene)
Study: 29562041
Drug: Case management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management model with individual training on hypertension causes, risk factors, significance, unwanted side effects, medication treatment, and lifestyle changes.
Study: 24044709
Drug: 810-nm subthreshold
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 810-nm subthreshold diode micropulse (SDM) laser treatment
Study: 11514368
Drug: High-dose gamma-irradiation
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gamma-irradiation (18 Gy at 2 mm from the source)
Study: 9024023
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg IV administered at the end of surgery
Study: 9024023
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg IV administered before induction of anesthesia
Study: 9024023
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 5 mL) administered prior to induction and at the end of surgery
Study: 25376140
Drug: Arthrocentesis (AC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis (AC) with corticosteroids (dexamethasone 8 mg)
Study: 7559887
Drug: GHRH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH plus atenolol (1 mg/kg)
Study: 1641600
Drug: roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 150 mg b.i.d.